Exelixis
EXEL
#1694
Rank
โ‚ฌ10.25 B
Marketcap
38,10ย โ‚ฌ
Share price
-0.02%
Change (1 day)
11.91%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2025 (TTM): โ‚ฌ0.77 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚ฌ2.28 Billion. In 2024 the company made an earning of โ‚ฌ0.58 Billion, an increase over its 2023 earnings that were of โ‚ฌ0.22 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) โ‚ฌ0.77 B32.93%
2024 โ‚ฌ0.58 B164.69%
2023 โ‚ฌ0.22 B9.89%
2022 โ‚ฌ0.20 B-20.33%
2021 โ‚ฌ0.25 B124.82%
2020 โ‚ฌ0.11 B-67.14%
2019 โ‚ฌ0.34 B-11.94%
2018 โ‚ฌ0.38 B185.09%
2017 โ‚ฌ0.13 B-325.82%
2016 -โ‚ฌ60.32 Million-58.12%
2015 -โ‚ฌ0.15 Billion-37.61%
2014 -โ‚ฌ0.24 Billion9.75%
2013 -โ‚ฌ0.22 Billion65.96%
2012 -โ‚ฌ0.13 Billion-291.63%
2011 โ‚ฌ66.12 M-195.59%
2010 -โ‚ฌ69.18 Million-42.17%
2009 -โ‚ฌ0.12 Billion-18.98%
2008 -โ‚ฌ0.15 Billion-6.99%
2007 -โ‚ฌ0.16 Billion46.3%
2006 -โ‚ฌ0.11 Billion33.25%
2005 -โ‚ฌ81.44 Million-30.92%
2004 -โ‚ฌ0.12 Billion44.29%
2003 -โ‚ฌ81.7 Million12.86%
2002 -โ‚ฌ72.4 Million22.79%
2001 -โ‚ฌ58.96 Million60.14%
2000 -โ‚ฌ36.82 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
GlaxoSmithKline
GSK
โ‚ฌ8.00 B 967.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚ฌ7.81 B 942.07%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚ฌ19.83 B 2,544.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ6.89 B 819.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚ฌ7.08 B 844.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚ฌ27.82 B 3,609.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ10.17 B 1,257.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-โ‚ฌ27.97 Million-103.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚ฌ24.95 Million-103.33%๐Ÿ‡บ๐Ÿ‡ธ USA